DIC complete guide from Harrison, tintinaali and other updates for emergency physician
Reading File
Finding Sources
Searching PubMed
"disseminated intravascular coagulation" AND management
Searching the Web
DIC disseminated intravascular coagulation 2024 2025 guidelines emergency management
Reading File
Finding Sources
Finding Sources
Reading Article
Reading File
Reading File
Reading File
Reading Web Page
ISTH DIC score 2025 updated criteria scoring
Reading File
Reading File
Reading Article
Reading File
Reading File
Loading Image
Reading File
Reading File
I now have comprehensive, rich content from all key sources. Let me compile the complete guide.
Disseminated Intravascular Coagulation (DIC): Complete Guide for Emergency Physicians
Sources: Harrison's Principles of Internal Medicine 22E (2025), Tintinalli's Emergency Medicine, Rosen's Emergency Medicine, ISTH 2025 Updated Criteria, Japan 2024 Clinical Practice Guidelines
1. DEFINITION
Classic (ISTH 2001): An acquired syndrome characterized by intravascular activation of coagulation with loss of localization, arising from different causes, that can originate from and cause damage to the microvasculature, which if sufficiently severe, can produce organ dysfunction.
Updated ISTH 2025 Definition: "An acquired, life-threatening intravascular disorder characterized by systemic coagulation activation, dysregulated fibrinolysis, and endothelial injury, resulting in microthrombosis. DIC arises from various underlying etiologies and progresses from a potentially asymptomatic early phase to an advanced phase with hemorrhage and/or organ dysfunction."
Key innovations in the 2025 update:
- Phase-based classification: Pre-DIC → Early-phase DIC (subclinical/compensated) → Overt DIC
- Phenotypic classification: Thrombotic DIC (microvascular thrombosis + organ failure) vs. Hemorrhagic DIC (factor consumption + bleeding)
- Sepsis-Induced Coagulopathy (SIC) score now recognized as an early-phase detection tool
- Revised D-dimer thresholds (see scoring below)
2. PATHOPHYSIOLOGY
The central driver is uncontrolled thrombin generation, with simultaneous disruption of physiologic anticoagulant mechanisms and abnormal fibrinolysis.
Pathophysiology of DIC: Uncontrolled thrombin generation leads to fibrin deposits in the microcirculation and consumption of platelets/coagulation factors, resulting in ischemic organ failure and diffuse bleeding via secondary fibrinolysis (FDP/D-dimer). - Harrison's 22E, Fig. 121-4
Step-by-step cascade (Rosen's):
- Platelets and coagulation factors are consumed (especially fibrinogen, factors V, VIII, XIII)
- Thrombin is formed - overwhelms its inhibitor system, directly activates fibrinogen
- Fibrin is deposited in small vessels of multiple organs
- Plasmin lyses fibrin and impairs thrombin formation (secondary fibrinolysis)
- Fibrin degradation products (FDPs) are released - impair platelet function and inhibit fibrin polymerization
- Coagulation inhibitors (antithrombin III, protein C, TFPI) are depleted
Thrombo-inflammation (Harrison's 22E): In sepsis, activation of inflammatory pathways increases tissue factor expression, activates neutrophils/monocytes with cytokine release, generates neutrophil extracellular traps (NETs), and releases polyphosphates that engage the coagulation system. Endothelial damage strips native antithrombotic properties.
Purpura fulminans is a severe DIC variant - extensive skin thrombosis, predominantly in young children post-viral/bacterial infection, associated with protein C pathway deficiencies.
3. CAUSES / PRECIPITANTS
| Category | Specific Causes / Key Notes |
|---|---|
| Infection (most common) | Gram-negative sepsis (10-20% develop DIC); endotoxins stimulate TF expression on monocytes/endothelium. Rocky Mountain spotted fever causes direct endothelial damage. More likely thrombosis than bleeding in sepsis. Asplenic/cirrhotic patients at higher risk |
| Malignancy | Adenocarcinoma (mucin-producing) - tends toward thrombosis (Trousseau's syndrome); AML (esp. APML/M3) - blast cells release procoagulant enzymes, excessive release at cell lysis → bleeding; lymphoma; prostate cancer - tends toward bleeding |
| Trauma | Brain injury, crush injury, burns, hypothermia/hyperthermia, rhabdomyolysis, fat embolism, hypoxia - massive bleeding can occur |
| Obstetric | Placental abruption, amniotic fluid embolism, septic abortion, dead fetus syndrome (chronic DIC), HELLP syndrome |
| Vascular | Large aortic aneurysm (chronic DIC → acute at surgery), giant hemangiomas (Kasabach-Merritt), vasculitis |
| Organ injury | Acute hepatic failure (TF from injured hepatocytes), pancreatitis, ALI/ARDS (20% of ALI develop DIC; 20% of DIC develop ALI) |
| Immunologic | Acute hemolytic transfusion reaction (DIC + severe bleeding + shock + acute renal failure), graft-vs-host disease, transplant rejection |
| Envenomation | Rattlesnakes and vipers - endothelial damage; bleeding not as severe as labs suggest |
| Drugs | Fibrinolytic agents, aprotinin, warfarin (neonates with protein C deficiency), PCCs, amphetamines |
4. CLINICAL PRESENTATION
Acute DIC:
- Petechiae, ecchymoses, purpura
- Bleeding from venipuncture sites - hallmark finding
- Severe hemorrhage: GI tract, lung, CNS
- Microvascular thrombosis → organ dysfunction (renal failure, hepatic failure, CNS changes, ARDS)
- Hemodynamic instability/shock (from underlying disease)
- Mortality 30-80%
Chronic/Compensated DIC:
- Discrete bleeding limited to skin or mucosal surfaces
- Associated with giant hemangioma, metastatic carcinoma, late-gestation fetal demise
- Labs: Elevated FDPs/D-dimer, near-normal PT/aPTT/fibrinogen, mild thrombocytopenia or normal platelet count
Red Flags requiring urgent workup:
- Purpura + bleeding tendency + signs of organ injury (CNS, kidney)
- Oozing from IV sites after sepsis, trauma, obstetric complication, or malignancy
- Thrombosis in unusual locations + concurrent bleeding
5. LABORATORY DIAGNOSIS
Core Labs (order all simultaneously)
| Test | Finding | Pathophysiology |
|---|---|---|
| Platelet count | Usually low (<100,000/mm³), or dropping trend | Consumed in clotting |
| PT | Prolonged | Factors II, V, VII, X consumed (factor VII has shortest half-life - falls first) |
| aPTT | Usually prolonged | Factors II, V, VIII consumed |
| Thrombin time | Prolonged | Factor II consumed + decreased fibrinogen + in vivo fibrinolysis |
| Fibrinogen | Low - but may be normal/elevated early (acute-phase reactant!) | Fibrinogen <100 mg/dL = severe DIC |
| D-dimer / FDPs | Elevated (sensitive but not specific) | Secondary fibrinolysis; D-dimer markedly elevated in DIC vs. normal/minimal in liver disease |
| Peripheral smear | Schistocytes, RBC fragments, low platelets | RBC fragmentation on fibrin strands (not always present) |
| Creatinine/UA | May be abnormal | Renal microvascular fibrin deposition |
| Factor assays | Extrinsic pathway most affected: factors VII (falls first), X, V, II low; Factor VIII variable (acute-phase reactant) | - |
Key clinical pearl: In critically ill patients, labs must be repeated every 6-8 hours as patients can rapidly deteriorate. The trend matters more than a single value.
Fibrinogen is tricky: As an acute-phase reactant, it may start elevated. Normal fibrinogen does NOT rule out DIC. Only a frankly low fibrinogen (<100 mg/dL) is diagnostic weight.
6. DIAGNOSTIC SCORING
ISTH Overt DIC Score (Updated 2025)
Only apply when an underlying condition known to cause DIC is present
| Parameter | Value | Points |
|---|---|---|
| Platelet count | ≥100 × 10⁹/L | 0 |
| 50-<100 × 10⁹/L | 1 | |
| <50 × 10⁹/L | 2 | |
| D-Dimer | >7× upper normal limit | 3 |
| >3× upper normal limit | 2 | |
| Normal | 0 | |
| PT prolongation | ≥6 seconds | 2 |
| ≥3s - <6s | 1 | |
| <3s | 0 | |
| Fibrinogen (Clauss) | <100 mg/dL (<1 g/L) | 1 |
| >100 mg/dL (>1 g/L) | 0 |
Score ≥5 = Overt DIC (repeat labs daily)
Score <5 = Low-grade/Non-overt DIC (repeat every 1-2 days)
Maximum score = 8 points
Not to be used in pregnant patients
2025 Update: D-dimer thresholds revised - >3× UNL = 2 points, >7× UNL = 3 points (previously used "moderate/severe increase" without numerical anchors). This makes scoring institution-independent when UNL is known.
Sepsis-Induced Coagulopathy (SIC) Score - Early-phase DIC detection
| Parameter | Value | Points |
|---|---|---|
| PT-INR | 1.2-1.4 | 1 |
| >1.4 | 2 | |
| Platelet count | 100-150 × 10⁹/L | 1 |
| <100 × 10⁹/L | 2 | |
| SOFA score | ≥2 | 2 |
SIC Score ≥4 = Significant (associated with increased mortality and progression to overt DIC)
7. DIFFERENTIAL DIAGNOSIS
| Condition | Key Differentiating Features |
|---|---|
| Severe liver disease | Jaundice + splenomegaly clinically; lab abnormalities are stable (not rapidly worsening); D-dimer minimally elevated; no schistocytes |
| Primary fibrinolysis | Rare; plasmin generated without thrombin; platelets, factor V, and factor VIII preserved in low-normal range; D-dimer minimal/normal |
| TTP/HUS | Thrombocytopenia + microangiopathic hemolytic anemia + multiorgan failure; but ADAMTS13 inhibitor present; PT/aPTT typically normal; fibrinogen normal |
| Heparin-induced thrombocytopenia (HIT) | Paradoxical thrombosis; 4Ts score; positive anti-PF4 antibody |
| ITP | Isolated thrombocytopenia; no coagulopathy; normal PT/aPTT/fibrinogen/D-dimer |
Critical differentiating point: In DIC, labs deteriorate rapidly. In liver disease, they are relatively stable. The dynamic change is the key feature.
8. MANAGEMENT
Overarching Principle
DIC is always secondary. The #1 priority is identifying and treating the underlying cause. Many cases of DIC are self-limited (transfusion reaction) or compensated (tumor-associated) and require only supportive care.
Step-by-Step Emergency Approach
Step 1: Treat the precipitating cause
- Sepsis: antibiotics, source control, fluid resuscitation, vasopressors per Surviving Sepsis Campaign
- Obstetric emergency: delivery of fetus/placenta
- Trauma: damage control resuscitation, hemorrhage control
- APML: initiate ATRA (all-trans retinoic acid) + arsenic trioxide urgently
- Acute hemolytic transfusion reaction: stop transfusion immediately
Step 2: Decide if specific DIC management is needed
Specific management is warranted if the patient has:
- Active bleeding
- Significant bleeding risk requiring an invasive procedure
- Arterial or venous thromboembolism
- Skin necrosis or acral ischemia
Asymptomatic DIC or mildly abnormal labs alone do NOT require blood products.
Blood Product Replacement (Hemorrhagic DIC)
| Product | Indication | Dose | Target |
|---|---|---|---|
| Platelets | Active bleeding + platelets <50,000/mm³ OR high-risk (chemotherapy) + platelets <20,000-30,000/mm³ | Standard dose | >50,000 if bleeding |
| Fresh Frozen Plasma (FFP) | Bleeding + PT/aPTT >1.5× normal OR fibrinogen <100 mg/dL (<1 g/L) | 15 mL/kg (some evidence 30 mL/kg superior when volume overload not a concern) | PT prolonged ≤3s above UNL |
| Cryoprecipitate | Low fibrinogen + active bleeding; volume-restricted patients | Per hematology guidance | Fibrinogen >150 mg/dL |
| Fibrinogen concentrate | Alternative to cryo as fibrinogen source | Per hematology guidance | Fibrinogen >150 mg/dL |
| PRBCs | Maintain hemodynamic stability and adequate Hgb | As needed | Hemodynamic stability |
| Vitamin K | Always give (corrects any concurrent vitamin K deficiency) | 10 mg IV/PO | - |
Monitoring response: Slowing of bleeding + decrease in FDPs + rise in platelet count + rise in fibrinogen = improvement. Normalization of clotting times occurs later - less useful for initial monitoring.
Anticoagulation in DIC (Thrombotic DIC)
Heparin is selectively indicated when fibrin deposition and thrombosis predominate:
Use heparin in:
- Purpura fulminans
- Retained nonviable fetus before delivery
- Giant hemangioma (Kasabach-Merritt)
- Acute promyelocytic leukemia (APML)
- Solid tumor-associated chronic DIC
- Dose: Low-dose continuous infusion UFH (5-10 U/kg/h) or LMWH
Do NOT use heparin in:
- Meningococcemia
- Abruptio placentae
- Severe liver disease
- Trauma-related DIC
- General postoperative DIC
Continuous monitoring of clinical response, heparin activity levels, and bleeding status is essential when using anticoagulation.
Advanced/Adjunct Therapies
| Agent | Evidence | Current Recommendation |
|---|---|---|
| Antithrombin (AT) concentrate | Japan 2024 Guidelines: GRADE 1B for DIC with sepsis | Recommended in sepsis-DIC (Japan guidelines); variable use in Western practice |
| Recombinant thrombomodulin | Japan 2024 Guidelines: GRADE 1B for DIC with sepsis | Recommended in sepsis-DIC (Japan); not widely available in all countries |
| Antifibrinolytics (TXA, EACA) | Limited evidence; risk of thrombosis | Consider only in primary hyperfibrinolytic state (APML, giant hemangioma) with severe bleeding; use cautiously with concurrent heparin |
| Recombinant factor VIIa | No improved outcome in DIC | Not recommended |
| Activated protein C | No improved outcome in DIC | Not recommended (withdrawn) |
| PCC (4F-PCC) | No demonstrated benefit in DIC | Not indicated for DIC (indicated for warfarin reversal) |
9. SPECIAL CLINICAL SCENARIOS
DIC in Sepsis
- Thrombosis more common than bleeding in early sepsis-DIC
- SIC score useful for early detection
- Antithrombin + recombinant thrombomodulin GRADE 1B (Japan 2024 Guidelines - PMID 39676120)
- Prophylactic LMWH recommended for VTE prevention (not full-dose anticoagulation)
DIC in Trauma
- Massive hemorrhage dominates
- Prioritize damage control resuscitation: 1:1:1 ratio (PRBCs:FFP:platelets) or whole blood
- Cryoprecipitate early to maintain fibrinogen
- Tranexamic acid within 3 hours of injury (CRASH-2 evidence)
- Hypothermia worsens DIC - actively warm patient
DIC in Obstetrics
- Placental abruption, amniotic fluid embolism, HELLP syndrome, septic abortion
- Modified ISTH score (exclude D-dimer, use platelets + fibrinogen + PT vs. lab control) - sensitivity 88%, specificity 96%
- Fibrinogen <200 mg/dL in pregnancy is concerning (normal is higher in pregnancy)
- Definitive treatment = delivery
DIC in APML (M3 Leukemia)
- Bleeding predominates (worst DIC in malignancy)
- Blast cells release procoagulant enzymes; worsens at cell lysis during chemotherapy
- Urgent ATRA + arsenic trioxide - reduces DIC by differentiating blasts
- Platelet transfusion target: >30,000-50,000/mm³
- Consider antifibrinolytics
- Heparin only if clear thrombosis
DIC in Snake Envenomation
- Endothelial damage; interestingly, bleeding is often less severe than labs suggest
- Antivenom is definitive treatment
- Supportive blood product replacement
10. DISPOSITION
- Admit all patients with active DIC or significant unexplained coagulopathy
- ICU-level care for hemodynamically unstable, multi-organ involved, or rapidly deteriorating DIC
- Transfer if hematologic expertise is unavailable (especially for APML)
- Repeat labs every 6-8 hours in critically ill patients
- Early hematology consultation for complex/refractory cases
11. PEARLS FOR THE EMERGENCY PHYSICIAN
- Think DIC in any patient with: Sepsis + bleeding from IV sites + thrombocytopenia + elevated PT/PTT
- The trend beats the single value - repeat labs every 6-8 hours; rapidly worsening labs = DIC until proven otherwise
- Normal fibrinogen does NOT exclude DIC - it's an acute-phase reactant; it may start high and fall
- D-dimer markedly elevated in DIC vs. only mildly elevated in liver disease or primary fibrinolysis
- Don't transfuse for lab values alone - only transfuse for active bleeding or high-risk procedures
- Heparin is harmful in trauma/abruption - only use when thrombosis dominates
- APML is the one malignancy requiring emergent hematology - ATRA can be life-saving before DIC worsens
- Obstetric DIC = delivery is the treatment - support coagulation until the uterus is emptied
- TTP/HUS mimics DIC but PT/aPTT are typically normal in TTP - check ADAMTS13
- 2025 ISTH update: DIC now has early/pre-clinical phase detection - SIC score ≥4 in sepsis patients warrants close monitoring even before overt DIC criteria are met
12. EPIDEMIOLOGY & PROGNOSIS (ISTH 2025 Meta-analysis)
From the 2025 ISTH SSC systematic review and meta-analysis (PMID 40383152, J Thromb Haemost 2025):
| Underlying Disease | Pooled Raw Mortality | Odds Ratio for Mortality vs. No DIC |
|---|---|---|
| Sepsis | 42% | 3.15× |
| Trauma | 36% | 4.80× |
| Leukemia | 28% | - |
| Heat stroke | 32% | - |
| Snakebite | 8% | - |
Critical finding: No clear yearly trend of improvement in mortality has been observed despite decades of treatment efforts - underscoring the importance of early recognition and treating the underlying cause.
Key References
- Harrison's Principles of Internal Medicine, 22nd Edition (2025), Chapter 121 - Disseminated Intravascular Coagulation
- Tintinalli's Emergency Medicine, 9th Edition, Chapter 233 - Disseminated Intravascular Coagulation
- Rosen's Emergency Medicine, 10th Edition, Chapter 111 - Disseminated Intravascular Coagulation
- Iba T, et al. Updated definition and scoring of DIC in 2025: ISTH SSC communication. J Thromb Haemost. 2025;23(7):2356-62
- Umemura Y, et al. Mortality, diagnosis, and etiology of DIC - systematic review and meta-analysis, ISTH 2025. J Thromb Haemost. 2025 (PMID 40383152)
- Yamakawa K, et al. Japan 2024 DIC Guidelines Part 1: Sepsis (GRADE 1B antithrombin + thrombomodulin). Int J Hematol. 2025 (PMID 39676120)
- Hayakawa M, et al. Japan 2024 DIC Guidelines Part 4: Trauma, burns, obstetrics. Int J Hematol. 2025 (PMID 39890756)
Sepsis hour bundle in exam format detailed information according to latest guidelines
Reading File
Finding Sources
Searching PubMed
"sepsis bundle" AND "hour-1" AND guidelines
Searching the Web
Surviving Sepsis Campaign 2024 2025 hour-1 bundle updated guidelines SSC
Reading Web Page
sepsis hour-1 bundle antibiotics fluids vasopressors lactate blood cultures 2026 recommendations
Finding Sources
Searching PubMed
"surviving sepsis campaign" AND guidelines AND 2021
Reading Web Page
hour-1 bundle antibiotics fluid resuscitation vasopressors norepinephrine MAP lactate septic shock recommendations 2026
Finding Sources
Finding Sources
Reading File
Reading File
Searching the Web
SSC 2026 sepsis guidelines full recommendations antibiotics antimicrobial timing fluid crystalloid vasopressor lactate
Reading Web Page
SSC 2026 full bullet point recommendations sepsis bundle antibiotics steroids source control lactate vasopressor norepinephrine
Reading File
I now have comprehensive, detailed data from the SSC 2026 guidelines, Tintinalli's, Fischer's Surgery, and supporting sources. Let me now compile the complete exam-format guide.
Sepsis Hour Bundle: Complete Exam-Format Guide
According to Latest Guidelines - SSC 2026 (Published March 23, 2026)
Sources: Surviving Sepsis Campaign (SSC) 2026 International Guidelines, Tintinalli's Emergency Medicine 9e, Fischer's Mastery of Surgery 8e, CMS SEP-1 Core Measure
SECTION 1: DEFINITIONS (Sepsis-3 / Exam Favorite)
| Term | Definition | Criteria |
|---|---|---|
| Sepsis | Life-threatening organ dysfunction caused by a dysregulated host response to infection | Suspected/proven infection + SOFA score increase ≥2 from baseline |
| Septic Shock | Subset of sepsis where circulatory/cellular metabolic abnormalities substantially increase mortality | Sepsis + vasopressor requirement to maintain MAP ≥65 mmHg + lactate >2 mmol/L despite adequate fluid resuscitation |
| qSOFA | Bedside screening tool (NOT for diagnosis) | Altered mentation + RR ≥22/min + SBP ≤100 mmHg; score ≥2 = high risk |
Exam note: qSOFA is not recommended by SSC 2021/2026 for sepsis screening or diagnosis due to low sensitivity. Full SOFA score is preferred. qSOFA is a risk stratification tool only.
SECTION 2: SOFA SCORE (Sequential Organ Failure Assessment)
| Organ System | Parameter | Score 1 | Score 2 | Score 3 | Score 4 |
|---|---|---|---|---|---|
| Respiration | PaO₂/FiO₂ | <400 | <300 | <200 (ventilated) | <100 (ventilated) |
| Coagulation | Platelets (×10³/µL) | <150 | <100 | <50 | <20 |
| Liver | Bilirubin (mg/dL) | 1.2-1.9 | 2.0-5.9 | 6.0-11.9 | >12 |
| Cardiovascular | MAP or vasopressors | MAP <70 | Dopamine ≤5 or dobutamine | Dopamine 5.1-15 or NE/Epi ≤0.1 | Dopamine >15 or NE/Epi >0.1 |
| CNS | Glasgow Coma Scale | 13-14 | 10-12 | 6-9 | <6 |
| Renal | Creatinine (mg/dL) / UO | 1.2-1.9 | 2.0-3.4 | 3.5-4.9 or <500mL/day | >5.0 or <200mL/day |
SOFA ≥2 = organ dysfunction = sepsis criterion
(Baseline SOFA assumed 0 in patients without prior organ dysfunction)
SECTION 3: EVOLUTION OF THE BUNDLE
| Year | Bundle | Key Change |
|---|---|---|
| 2004-2012 | 2-hour + 6-hour bundle | Separate early/late resuscitation targets |
| 2012-2018 | 3-hour + 6-hour bundle | Streamlined; CVP and ScvO₂ targets removed |
| 2018 | Hour-1 Bundle (SSC update) | Previous 3- and 6-hour bundles merged into single 1-hour bundle |
| 2021 | SSC 2021 Guidelines | Hour-1 bundle retained; de-emphasized CVP; strengthened norepinephrine |
| 2026 | SSC 2026 Guidelines | 129 statements, 46 new; nuanced antibiotic timing; balanced crystalloids; MAP targets by age |
SECTION 4: THE HOUR-1 BUNDLE (5 Core Elements)
Mnemonic: BLAAF - Blood cultures, Lactate, Antibiotics, Administer fluids, Fix blood pressure (vasopressors)
Element 1: MEASURE LACTATE
| Aspect | Details |
|---|---|
| Action | Measure serum lactate level as soon as possible |
| SSC 2026 | "Suggest" measuring blood lactate (conditional, low certainty) |
| Clinical significance | Lactate >2 mmol/L = part of septic shock definition |
| Lactate >4 mmol/L | Triggers fluid resuscitation even without hypotension; associated with ~25-30% mortality |
| Serial lactate | SSC 2026: "Suggest" serial lactate measurements to guide resuscitation in sepsis with elevated lactate or septic shock (conditional, low certainty) |
| Lactate clearance | Target ≥10% decrease per 2 hours; indicates adequate resuscitation; failure to clear = higher mortality |
| Remark (2026) | Fluid administration should be individualized after initial bolus guided by lactate decrement - not continued until lactate normalization |
| Venous vs arterial | Both acceptable; use same method serially (arterial or venous) |
Exam pitfall: Lactate is NOT diagnostic for sepsis alone - it is also elevated in liver disease, metformin toxicity, epinephrine infusion, seizures, severe asthma. It is a prognostic/resuscitation tool.
Element 2: OBTAIN BLOOD CULTURES BEFORE ANTIBIOTICS
| Aspect | Details |
|---|---|
| SSC 2026 | "Recommend" collecting blood cultures as soon as possible, ideally before antimicrobial therapy (strong recommendation, low certainty) |
| Number of sets | 2 sets - one aerobic + one anaerobic per set |
| When to not delay antibiotics | Do NOT delay antibiotics >45 minutes to obtain cultures |
| Additional cultures | Peritoneal fluid, urine, sputum, wound cultures based on suspected source |
| Clinical rationale | Blood cultures become sterile after just 1 dose of appropriate antibiotics |
| Novel diagnostics | SSC 2026: "Insufficient evidence" for novel rapid host response diagnostics |
Element 3: ADMINISTER BROAD-SPECTRUM ANTIBIOTICS
Timing (2026 - Critical Exam Topic)
| Sepsis Category | SSC 2026 Recommendation | Strength/Certainty |
|---|---|---|
| Probable or definite sepsis (with or without shock) | Antibiotics immediately, ideally within 1 hour of recognition | Strong recommendation, very low certainty |
| Possible sepsis without shock | Time-limited rapid investigation → if infection likely, antibiotics within 3 hours | Conditional, very low certainty |
| Possible or definite septic shock | Antibiotics immediately, within 1 hour | Strong recommendation, very low certainty |
| Prehospital (transport time likely >60 min) | Suggest prehospital antibiotics (conditional, very low certainty - NEW 2026) | Only with sepsis screening tool |
Key 2026 change: The distinction between "probable/definite" vs. "possible" sepsis introduces nuance - for possible sepsis without shock, a brief assessment window (up to 3 hours) is acceptable to avoid unnecessary antibiotics.
Antibiotic Selection Principles (SSC 2026)
| Principle | Recommendation |
|---|---|
| Empiric coverage | Broad-spectrum targeting likely pathogens based on clinical syndrome, local resistance patterns |
| Anaerobic coverage | NEW 2026: Suggest empiric antibiotics without anaerobic coverage UNLESS risk factors present (conditional, very low certainty) |
| Risk factors requiring anaerobic coverage | Intraabdominal/gyn-OB source, necrotizing soft tissue infection, HEENT infection, CNS abscess/empyema |
| Anti-MRSA coverage | Add if risk factors: prior MRSA infection, known colonization, healthcare-associated infection, structural lung disease |
| Anti-pseudomonal coverage | Add if risk factors: prior Pseudomonas infection, recent broad-spectrum antibiotics, structural lung disease |
| Duration | Typically 7-10 days; de-escalate based on cultures/clinical response; procalcitonin can guide de-escalation |
| De-escalation | Narrow spectrum once culture results available; discontinue if infection excluded |
Common Empiric Regimens by Source
| Source | Empiric Regimen (general principles) |
|---|---|
| Unknown/community | Piperacillin-tazobactam OR 3rd/4th gen cephalosporin ± metronidazole |
| Intraabdominal | Piperacillin-tazobactam OR carbapenem (meropenem) + antifungal if high risk |
| Pulmonary | Beta-lactam + macrolide OR respiratory fluoroquinolone |
| UTI/urosepsis | 3rd gen cephalosporin OR piperacillin-tazobactam |
| Healthcare-associated | Carbapenem ± vancomycin/linezolid |
| Neutropenic | Antipseudomonal beta-lactam (cefepime/pip-tazo/carbapenem) |
Element 4: ADMINISTER IV FLUID RESUSCITATION
| Aspect | SSC 2026 Recommendation | Strength/Certainty |
|---|---|---|
| When to give fluids | Sepsis-induced hypoperfusion or septic shock | - |
| Volume | At least 30 mL/kg IV crystalloid within the first 3 hours | Conditional, low certainty |
| Important note (2026) | Use adjusted or ideal body weight for patients with BMI >30 | Remark (new 2026) |
| Fluid type - first line | Crystalloids (not colloids) | Strong recommendation, moderate certainty |
| Balanced vs. saline | Balanced crystalloids (Lactated Ringer's, PlasmaLyte) preferred over 0.9% saline | Conditional, moderate certainty |
| Exception | For sepsis with traumatic brain injury - use 0.9% saline (balanced solutions may worsen ICP) | |
| Colloids | Do NOT use hydroxyethyl starch (increased renal failure + mortality); albumin may be used as adjunct if large volumes of crystalloid required | |
| Beyond initial bolus | Guided by dynamic assessment of fluid responsiveness; not driven by fixed protocols or CVP | |
| Reassessment | Frequent ongoing reassessment to avoid under- or over-resuscitation |
Fluid Responsiveness Assessment Techniques
- Passive leg raise (PLR) - most validated; SV increase ≥10% = fluid responsive
- Pulse pressure variation (PPV) - valid only in mechanically ventilated patients, no arrhythmias
- Stroke volume variation (SVV)
- Point-of-care echo (POCUS) - IVC collapsibility, LV function
Exam pearl: The 30 mL/kg is a starting point, not a target. Over-resuscitation is harmful. Always reassess after initial bolus.
Element 5: VASOPRESSORS (If Hypotension Persists)
Timing of Vasopressor Initiation
| Scenario | SSC 2026 Recommendation |
|---|---|
| Sepsis-induced hypotension | Suggest initial IV crystalloid bolus first → vasopressors if hypotension persists (conditional, very low certainty) NEW 2026 |
| Unstable septic shock | Immediate concurrent vasopressors + IV crystalloid is appropriate (individualized) |
| Signs of unstable shock | Severely reduced BP, mottled skin, ashen appearance, cyanosis/↓O₂ sat, tachycardia, altered mentation |
| Peripheral vasopressors | NEW 2026: Suggest starting vasopressors peripherally to restore MAP rather than delaying until central venous access secured (conditional, very low certainty) |
Vasopressor Choice (Hierarchy)
| Vasopressor | Recommendation | Evidence |
|---|---|---|
| Norepinephrine (NE) | FIRST-LINE for septic shock | Strong recommendation (against dopamine/epi/selepressin); downgraded to conditional over vasopressin/Ang II in 2026 |
| Vasopressin | Add to NE if MAP target not achieved, to reduce NE dose | Conditional, low certainty - NE now conditional "first" over vasopressin (downgrade from 2021) |
| Epinephrine | Add to NE + vasopressin if MAP still inadequate (conditional, very low certainty) OR use alone if concomitant cardiac dysfunction (conditional, very low certainty) | |
| Angiotensin II | NEW 2026: Suggest Ang II as adjunctive vasopressor for refractory septic shock (conditional, very low certainty) | |
| Dopamine | NOT recommended as first-line (increased arrhythmias); only in highly selected patients | |
| Selepressin | NOT recommended |
MAP Targets (2026)
| Population | MAP Target | Strength/Certainty |
|---|---|---|
| General adults with septic shock | ≥65 mmHg (allow range within 5 mmHg, e.g., 60-70 mmHg) | Strong, moderate certainty |
| Adults ≥65 years | 60-65 mmHg (lower target acceptable) - NEW 2026 | Conditional, low certainty |
Inotropes
| Indication | Recommendation |
|---|---|
| Septic shock + cardiac dysfunction + persistent hypoperfusion despite adequate fluid/MAP | Suggest adding dobutamine to NE OR using epinephrine alone (conditional, very low certainty) |
| Note | Inotropes added in addition to vasopressors, not instead of them |
SECTION 5: CMS SEP-1 CORE MEASURE vs. SSC Bundle
(Distinction frequently tested in board exams)
| Parameter | CMS SEP-1 | SSC Hour-1 Bundle |
|---|---|---|
| Definition framework | Uses older severe sepsis/septic shock definitions | Uses Sepsis-3 definitions |
| Lactate | Measure within 3 hrs; remeasure if >2 mmol/L (within 6 hrs) | Measure immediately |
| Blood cultures | Before antibiotics (within 3 hrs) | Before antibiotics (immediately) |
| Antibiotics | Within 3 hrs for severe sepsis/shock | Within 1 hour (probable/definite) or 3 hrs (possible) |
| Fluids | 30 mL/kg within 3 hrs | 30 mL/kg within 3 hrs |
| Vasopressors | For persistent hypotension (after fluids) | MAP ≥65 during or after fluids |
| Reassessment | Required for persistent shock | Ongoing dynamic reassessment |
SECTION 6: ADDITIONAL MANAGEMENT (Beyond the Bundle)
Source Control
- Mandatory for all sepsis patients - comprehensive search for infection source
- Drain abscesses, debride necrotic tissue, remove infected devices, drain infected collections
- As soon as feasible - antibiotics are far less effective without source control
- SSC 2026: Recommend source control with least invasive effective intervention
Corticosteroids
- Indication: Septic shock requiring vasopressors despite adequate fluid resuscitation
- SSC 2026: Suggest IV corticosteroids (conditional, low certainty - downgraded from moderate in 2021)
- Regimen: Hydrocortisone 200 mg/day IV continuous infusion OR 50 mg IV q6h
- When to use: Not to be given to treat sepsis without shock
- Do not use ACTH stimulation test to guide steroid use
Glucose Control
- Target blood glucose 140-180 mg/dL (7.8-10 mmol/L)
- Use insulin infusion protocols
- Avoid hypoglycemia
Procalcitonin (PCT)
- Useful to support antibiotic de-escalation and discontinuation decisions
- NOT to be used alone to initiate or withhold antibiotics
- SSC 2026: Suggest using PCT to shorten antibiotic duration
Blood Products
| Product | Threshold | Indication |
|---|---|---|
| RBC transfusion | Hgb <7 g/dL | Not in the absence of myocardial ischemia, severe hypoxemia, or hemorrhage |
| Platelets | <10,000 (prophylactic); <20,000 if risk of bleeding; <50,000 if active bleeding/procedure | |
| FFP/Cryo | Coagulopathy with active bleeding or planned invasive procedure |
Mechanical Ventilation in Sepsis-Induced ARDS
- Tidal volume 6 mL/kg predicted body weight
- Plateau pressure <30 cmH₂O
- PEEP titration (higher PEEP for moderate-severe ARDS)
- Prone positioning ≥12-16 hours/day for moderate-severe ARDS (PaO₂/FiO₂ <150)
- Avoid routine use of neuromuscular blockade; use in severe ARDS only
Renal Replacement Therapy
- Initiate when life-threatening metabolic or fluid abnormalities from AKI (hyperkalemia, acidosis, fluid overload unresponsive to diuretics, uremia)
- Do NOT initiate RRT solely based on creatinine elevation without other indications
SECTION 7: SEPSIS SCREENING TOOLS
| Tool | Components | Score | Notes |
|---|---|---|---|
| qSOFA | Altered mentation + RR ≥22 + SBP ≤100 | ≥2 = high risk | NOT for diagnosis; ED screening tool; low sensitivity |
| SIRS | Temp >38°C or <36°C, HR >90, RR >20, WBC >12k or <4k or >10% bands | ≥2 criteria | Nonspecific; now replaced by SOFA for definition |
| NEWS/MEWS | Vitals-based early warning score | Institution-specific | Used for initial triage |
| Sepsis-related | SOFA ≥2 + infection | - | Gold standard for definition |
SSC 2026: "Suggest using a standard sepsis screening tool over not" (conditional, very low certainty)
SECTION 8: HIGH-YIELD EXAM QUESTIONS & ANSWERS
Q1. What are the 5 elements of the Hour-1 Bundle?
A: (1) Measure lactate, (2) Obtain blood cultures before antibiotics, (3) Administer broad-spectrum antibiotics, (4) Administer 30 mL/kg crystalloid for hypotension or lactate >4, (5) Apply vasopressors to maintain MAP ≥65 mmHg.
Q2. What is the antibiotic timing in SSC 2026 for probable sepsis?
A: Within 1 hour of recognition. For possible sepsis without shock, within 3 hours after brief assessment (new 2026 nuance).
Q3. First-line vasopressor in septic shock?
A: Norepinephrine. Strong recommendation against dopamine, epinephrine (as first agent), and selepressin. Now conditional over vasopressin (downgraded 2026).
Q4. MAP target in septic shock?
A: ≥65 mmHg (general adults). 60-65 mmHg for adults ≥65 years (new 2026). Allow ±5 mmHg range in practice.
Q5. Preferred IV fluid type in sepsis?
A: Balanced crystalloids (LR, PlasmaLyte) over 0.9% normal saline. Exception: traumatic brain injury - use 0.9% saline.
Q6. Should you delay antibiotics to get blood cultures?
A: Do NOT delay antibiotics >45 minutes to obtain cultures. Obtain cultures rapidly and simultaneously administer antibiotics.
Q7. What lactate level triggers fluid resuscitation independent of blood pressure?
A: Lactate >4 mmol/L (even without hypotension).
Q8. What is septic shock definition?
A: Sepsis + vasopressor requirement to maintain MAP ≥65 + lactate >2 mmol/L despite adequate fluids.
Q9. When are anaerobic-covering antibiotics indicated per SSC 2026?
A: Intraabdominal/gyn-OB source, necrotizing STI, HEENT infection, CNS abscess/empyema. Otherwise, not routinely required.
Q10. What is the new SSC 2026 recommendation on peripheral vasopressors?
A: Start vasopressors peripherally (peripheral IV) to restore MAP rather than delaying until central line is placed (new 2026 recommendation).
Q11. qSOFA score ≥2 means?
A: High risk for poor outcome - it is a risk stratification/screening tool, NOT a diagnostic criterion. Do not use alone to make/exclude sepsis diagnosis.
Q12. What did SSC 2026 downgrade from previous guidelines?
A: (1) NE first over vasopressin (conditional, not strong), (2) Epinephrine for refractory shock (very low → VL certainty), (3) Dobutamine (VL certainty), (4) Corticosteroids (low certainty, from moderate).
Q13. What is the SEP-1 vs. SSC 2026 biggest difference?
A: SEP-1 uses older "severe sepsis" definitions and allows 3 hours for antibiotics in all cases; SSC 2026 uses Sepsis-3 definitions and requires antibiotics within 1 hour for probable/definite sepsis.
Q14. Fluid resuscitation - 30 mL/kg over how long?
A: Within the first 3 hours. In patients with BMI >30, use adjusted or ideal body weight (new 2026).
SECTION 9: QUICK MEMORY AID
HOUR-1 BUNDLE = BLAAF
B - Blood cultures (before antibiotics)
L - Lactate (measure; remeasure if >2)
A - Antibiotics (within 1 hour for probable/definite)
A - Administer fluids (30 mL/kg crystalloid)
F - Fix hypotension (vasopressors → MAP ≥65)
VASOPRESSOR LADDER (SSC 2026):
1st: Norepinephrine
2nd: Add Vasopressin (MAP still low)
3rd: Add Epinephrine (MAP still low)
OR: Angiotensin II (refractory shock - NEW 2026)
Cardiac dysfunction: Add Dobutamine to NE (or Epi alone)
FLUID RULE:
Type: Balanced crystalloid (LR > NS)
Volume: 30 mL/kg in first 3 hours
Exception: TBI → use NS
Colloids: No HES; albumin adjunct only
KEY REFERENCES
- Prescott H, Antonelli M, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026. Crit Care Med. 2026 Mar 23. doi:10.1097/CCM.0000000000007075
- Evans L, et al. Surviving Sepsis Campaign 2021 Guidelines. Intensive Care Med. 2021;47:1181-1247 (PMID 34599691)
- Desposito L, Bascara C. Review: Sepsis guidelines and core measure bundles. Postgrad Med. 2024 Sep (PMID 39092891)
- Tintinalli's Emergency Medicine, 9th Edition, Chapter 151 - Sepsis
- Fischer's Mastery of Surgery, 8th Edition - Management of Sepsis
This is a shared conversation. Sign in to Orris to start your own chat.